Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of Selective Laser Trabeculoplasty SLT at low energy compared to standard energy for treating glaucoma and ocular hypertension. The study also aims to determine if repeating low energy SLT once a year can better prevent or delay the need for daily eye drop medications than waiting to repeat standard energy SLT until its effects wear off. This is a Phase 3 randomized trial focusing on treatment optimization for these eye conditions. Participants initially receive SLT treatment at standard energy, where energy levels are adjusted to produce champagne bubbles as a sign of effectiveness. At 12 months, eligible participants are randomly assigned to receive repeat SLT either annually with low energy or as needed with standard energy. The low energy SLT involves 100 treatment spots delivered at a lower energy level, adjusted as needed to maintain optimal response, while the standard energy SLT uses higher energy levels with similar adjustments. One arm of the initial low energy SLT was discontinued after interim analysis. Throughout the study, participants undergo regular eye pressure measurements and monitoring up to 48 months. Researchers measure outcomes such as survival without needing additional treatment at 12 and 48 months, average intraocular pressure IOP over time, and incidence of IOP spikes. Participants will attend scheduled visits for assessments and treatment as needed, with the total study duration lasting several years to evaluate long-term effects and safety.
Actively Recruiting
Researchers are evaluating a bilingual digital shared decision-making tool called WePrEP, designed to improve communication between transgender women and their HIV pre-exposure prophylaxis PrEP service providers. The study focuses on helping transgender women choose the most suitable PrEP method, either oral or injectable cabotegravir CAB-LA, by addressing their unique concerns and enhancing adherence. This tool aims to support diverse English- and Spanish-speaking transgender women and their providers in selecting the best PrEP option for each individual. The study involves a randomized controlled trial with 69 transgender women assigned in a 21 ratio to either use WePrEP with their providers or receive standard care explanations based on CDC guidelines. Providers in the intervention group will use WePrEP on tablets to present key information and guide discussions about PrEP options and adherence strategies. Control group providers will give standard PrEP explanations without the tool. Providers will use WePrEP with multiple participants to provide feedback during the study. Participants will undergo assessments at enrollment and follow-up visits, including measuring feasibility and acceptability of WePrEP, as well as preliminary impact measures such as PrEP uptake, serum concentrations, and adherence behavior. Patient-provider communication, satisfaction, engagement, and shared decision-making will also be evaluated using validated scales and qualitative methods. The trial runs from early 2025 through 2027, with ongoing monitoring of outcomes relevant to PrEP use in transgender women.